Running Through Walls

Ashish Jha, Dean of Brown University's School of Public Health, speaks with Venrock partners Bryan Roberts and Bob Kocher about the chapters of his career in public health before, during, and after the pandemic. He shares what he got right and wrong during his time as White House COVID-19 coordinator, how he managed 40-50 media interviews a day, where we have work to do on public health issues, and more. 

Elizabeth Pemmerl, Chief Revenue Officer at GitHub, speaks with Venrock partner Ethan Batraski to discuss her nearly decade-long journey with GitHub. Pemmerl shares how she transitioned from working in the public sector to GitHub, go-to-market strategies, balancing developer vs. enterprise needs, changing developer behavior and more. 

David Stark, Chief Medical Officer at Morgan Stanley, speaks with Venrock partner Bob Kocher to discuss his career journey from practicing medicine to taking a non-clinical role in business. Stark shares how he views his role as Chief Medical Officer, advice for other doctors who want to transition out of practicing medicine, what he's proudest of at Morgan Stanley and more.

Alex Rosemblat, former Chief Marketing Officer at Datadog, speaks with Venrock partner Ethan Batraski to discuss his 11-year run at the helm of Datadog's Marketing Team and what's next for his career. Rosemblat shares insights into leading Datadog's go-to-market strategy, advice for other marketing leaders tackling this for a new product or company for the first time, his biggest learning from Datadog and more. During the conversation, Rosemblat recommended Digital CMO's Guide to Marketing Measurement by Bryan Semple.  Book mentioned: https://vnrk.co/3VuFvxg 

Heather Turner, CEO at Carmot Therapeutics, speaks with Venrock partner Nimish Shah to discuss her time as CEO. Turner shares how she guided the company through its acquisition by Roche, advice for other CEOs on the verge of an acquisition, her perspective on the GLP-1 market and what excites her about the future of biotech. 

Mark McKenna, chairman and CEO at Mirador Therapeutics, speaks with Venrock partner Nimish Shah to discuss his most recent role at Prometheus Biosciences and the beginning of his new company, Mirador. McKenna shares a behind-the-scenes look into leading Prometheus during its acquisition by Merck, why he started Mirador Therapeutics, advice for other CEOs, what he values in a team and more.

We have a special episode today because Venrock's 8th annual Healthcare Prognosis results are in! From drugs (e.g., GLP-1s, pricing negotiations) to fundraising and optimism around the equity market to cybersecurity and AI regulations - this year's survey covers it all. In this episode, partners Bryan Roberts and Bob Kocher sit down to share their perspectives on the most interesting findings.

Sami Inkinen, founder and CEO of Virta Health, speaks with Venrock partner Bob Kocher to discuss how Virta has evolved since he was on the podcast seven years ago. Inkinen shares how he views the GLP-1 craze, insights on his go-to-market strategy, advice for founders entering the healthcare market, and how Virta uses AI and technology. 

Latané Conant, Chief Revenue Officer at 6sense, speaks with Venrock partner Brian Ascher to discuss how her previous marketing role prepared her for her promotion to Chief Revenue Officer. Conant shares her approach to keeping product market fit, her opinion on Marketing Qualified Leads (MQLs), how AI could impact sales and marketing and more.

Isan Chen, CEO of MBrace Therapeutics, speaks with Venrock partner Racquel Bracken to discuss his career trajectory leading up to his founding of MBrace. Chen shares the impetus behind his decision to become an oncologist, why he switched from academic medicine to the industry side, lessons learned from years in drug development and more.

Patrick Conway, CEO of Optum Rx, sits down with Venrock partners Bryan Roberts and Bob Kocher to discuss his first few months on the job. Conway also shares his views on the best early metric indicators of success, the effectiveness of Medicare Advantage Star Ratings, the role of technology in value-based care and more.

Ed Park, co-founder and CEO of Devoted Health, sits down with Venrock partners Bryan Roberts and Bob Kocher to discuss the founding of Devoted. Park talks about his priorities for the next five years, the value he sees in AI and LLMs, Medicare Advantage industry changes, his favorite interview question for job candidates and more. 

Ying Huang, CEO of Legend Biotech, speaks with Venrock partner Nimish Shah about his career path to Legend Biotech and the lessons he learned from transitioning from Wall Street to an operating role. Huang also discusses what he prioritized when he first started the role, the most rewarding parts of his job and what characteristics he looks for when hiring people for his team. 

Brad Stulberg, best-selling author of The Practice of Groundedness and co-author of Peak Performance, speaks with Venrock partner Bob Kocher about Stulberg's new book, Master of Change: How to Excel When Everything is Changing—Including You. Stulberg and Kocher discuss ways to rethink change, the concept of rugged flexibility and paths for embracing and growing from life's constant instability.  

Senthil Sundaram, CEO of Terns Pharmaceuticals, speaks with Venrock's Nimish Shah about the lessons learned balancing personal health events while being CEO of a young company. Sundaram also discusses the "Working Genius" model, an approach focused on leveraging the types of work that bring an employee energy, and his attitude towards team-based leadership and how it propels growth in the workplace.  

Dr. Sheila Gujrathi, a biotech industry veteran with a strong track record as an entrepreneur, physician executive, translational scientist, board member, and drug developer, speaks with Venrock's Nimish Shah about the lessons learned in her career at biotech companies both big (Genentech) and small (Gossamer Bio, Receptos, Inc.). Dr. Gujrathi also discusses the importance of building a team of people with shared values, the most challenging parts of being a CEO, and how she's helping to push diversity in biotech forward.    

Sam Kintz, co-founder, and CEO of Enliven Therapeutics, speaks with Venrock partner Nimish Shah about the journey that led him to found Enliven. Kintz delves into lessons learned during his time at Roche Venture Fund, and how his time at Stemcentrx and Abbvie revealed what truly matters most to him – being a part of an entire drug development story. Kintz discusses his decision to pursue a reverse merger (and how he persuaded everyone involved to follow this path), what defines a great leader, and shares the best advice he received from one of his mentors.

Venrock partners Andrew Gottesdiener and Nimish Shah speak with Michael Henderson, CEO of Apogee Therapeutics, about his role's unique challenges and opportunities. Henderson discusses his accelerated career trajectory, valuable lessons that have helped shape his success, and Apogee's recent Series B financing round. Henderson delves into the importance of culture building, including Apogee's guiding principles (CORE: Care, Original, Resilient, Ego-Less), and his strategies for navigating a challenging biotech industry.  

Venrock's Nick Beim speaks with Steve Lockshin, founder of Vanilla, about lessons learned as a serial entrepreneur in wealth management services. Lockshin shares what drives him as an entrepreneur, the need for more digestible information in estate planning, and his most valuable lessons learned on the path to building Vanilla. Lockshin also discusses the importance of humility and how it helped guide his decisions as a business leader.

Venrock partner Nick Beim speaks with Bill McNabb, former chairman and CEO of Vanguard, an asset management company that pioneered low-cost investing for the consumer. McNabb shares important leadership lessons including the importance of being humble, having a clear definition of success, and knowing what makes a high-performing team. McNabb reveals significant decisions he made during his time at Vanguard, such as having “no layoffs” during a crisis, and highlights the importance of thinking long-term while still being agile.

Farzad Mostashari, founder and CEO of Aledade, speaks with Venrock's Bryan Roberts and Bob Kocher about improving the quality and efficiency of patient care with a focus on preventative care. With the recent launch of Aledade Care Solutions and new focus on Medicare Advantage, Mostashari delves into Aledade's efforts to scale and deliver where average primary care practices can't. Mostashari also reveals his approach to value based care incentive structure, and why building a valuable solution requires a long time horizon.

Venrock partners Bryan Roberts and Bob Kocher, speak with Heather Fernandez, co-founder and CEO of Solv, about Solv's mission, building more cap table diversity in tech, and the healthcare field today. Fernandez delves into Solv's Series C funding round where she created a special purpose vehicle (SPV) focused on women of color, bringing in first-time investors who wouldn't otherwise have access. Fernandez also shares how Solv is unlocking capacity with software, its pricing strategy, and its goals for the next 2-3 years.

Larry Hamann, co-founder, president, and CEO of Interdict Bio, speaks with Venrock Vice President Mariana Mihalusova about lessons learned from his career in drug discovery. Hamann delves into where his love for organic chemistry stems from and why inclusive environments are essential to building successful teams. He also speaks about the do's and don'ts when structuring collaborations with big pharma, when a drug is “good enough” to move forward in development and new approaches he's excited for.

Venrock partner Bob Kocher speaks with Dr. Drew Altman, CEO of the Henry J. Kaiser Family Foundation (KFF) and founding publisher of Kaiser Health News (KNH), about dealing with misinformation and skepticism with expertise and facts. Altman reveals how misinformation, fragmented media, and a broken political system exacerbate the public's low trust in experts. Altman discusses KHN's origin story, the importance of busting liars without elevating them, and his thoughts on the Inflation Reduction Act. 

Jim Del Favero, Head of Product at Figure, a fintech company using blockchain to help homeowners better tap their home equity, joins Venrock partner Brian Ascher to discuss what makes a great product manager. Del Favero reveals why great PMs focus on outcomes, not outputs, and critically think about the problem that needs to be solved. Del Favero and Ascher also talk through common mistakes PMs make, the engineering and PM relationship, and data-driven vs. years of experience decisions.

Venrock partner Brian Ascher speaks with Nicole Alvino, co-founder and CEO of Firstup, about effective workforce communication both digitally and in person. Alvino highlights fostering employee connection through authentic and transparent communication, using the power of video to drive engagement, and discusses expectations for corporate social responsibility. Plus, Alvino reveals a non-obvious lesson learned – employees want to hear from their peers (not just their leaders).

Company success is predicated on the people, according to Daversa Partners founder and CEO, Paul Daversa. Venrock partner Bryan Roberts chats with Daversa about the nuances of recruiting impactful senior-level leadership candidates who are a fit for the needs of the company. They cover hiring high will over high skill, understanding that candidates are stage sensitive and ways to avoid terminal hires. Daversa also discusses the intentionality of Dreamscape, the challenges, and the impact they've made thus far.

Venrock partner Andrew Gottesdiener speaks with Jigar Raythatha, former CEO of Constellation Pharmaceuticals, about lessons learned from his time at Constellation. As Constellation has evolved from an early-stage company to being acquired by MorphoSys, Raythatha dives into its many life-cycles, his heavy involvement in the recruitment process, and the decision to conduct a PIPE financing. Raythatha also shares the characteristics to look for in an investor syndicate and the challenges of scaling a public company.

Venrock partner Racquel Bracken speaks with Markus Renschler, President and CEO of Cyteir Therapeutics, to discuss the journey that led him to Cyteir, and the company's path to going public. Renschler dives into an important lesson his parents instilled in him from a young age, “be comfortable with being uncomfortable,” and explains how this lesson has played an important role in his career journey. As a practicing hematologist oncologist, Renschler highlights the value of people skills and how developing those skills can positively influence leadership style, recruiting, and even fundraising. Renschler shares some of his highs and lows along the drug development process, provides advice for young clinicians entering the industry, and how his experience as a practicing physician influences the decisions he makes as a CEO.  

With rising reports of Omicron in the United States, Venrock partner Bryan Roberts speaks with Dr. Charity Dean, CEO and co-founder of Public Health Company (PHC), to discuss her predictions and concerns for the latest Covid-19 variant. Dean and Roberts also talk about the long-term societal impacts of Covid, the severity of disease, and which groups are best protected. As Covid-19 revealed the cracks in the U.S. public health system, Dean shares how she anticipates public infrastructure to evolve, including more public and private sector partnerships. Dean delves into what led her to become a public health officer, the most exciting part of her first year as CEO at PHC, and her thoughts on her starring role in Michael Lewis's book The Premonition: A Pandemic Story. 

Brad Stulberg, bestselling author of the books ‘The Passion Paradox' and ‘Peak Performance,' joins Venrock partner Bob Kocher to discuss his newest book, ‘The Practice of Groundedness.' Stulberg offers a healthier, more sustainable model for success and dives into what groundedness means to him – a sense of feeling solid, stable, and whole; in a way that doesn't eliminate ambition. Stulberg highlights the value of being present and how his views on well-being and performance have evolved. Kocher and Stulberg also discuss the importance of active reading, how grit only works if you have the right fit, and how wisdom impacts peak performance in different disciplines. 

Venrock partner Bob Kocher speaks with Ashish Jha, MD, MPH, Professor and Dean at Brown University School of Public Health, about the importance of interdisciplinary approaches and knowledge translation in tackling big public health problems. Dr. Jha delves into the journey that led him to become Dean at Brown University and his thoughts on academia's role in sharing information with the public. Dr. Jha and Kocher discuss the challenges of allocating vaccines and investing more in public health and pandemic preparedness. Dr. Jha also shares his thoughts on how Covid-19 will evolve, what will happen when schools open up in the fall, and the negative impact of fragmented information.

Not knowing where items are located, what's in stock, or if they are properly priced cost the global retail industry more than a trillion dollars. Venrock partner David Pakman speaks with Brad Bogolea, co-founder and CEO of Simbe Robotics, about how Simbe's robot Tally is solving these major blind spots. Bogolea delves into how robotic solutions can keep up with rapid changes without overhauling infrastructure and provide greater optical data than traditional solutions. Bogolea discusses the competitive and consumer pressures prompting retailers to embrace robotic solutions and how the pandemic exposed the need for autonomy and better data. Bogolea also touches on the challenges of financing in the robotics sector, and how being customer-oriented is key to Simbe's success. 

Vlad Coric, M.D., CEO of Biohaven Pharmaceuticals, joins Venrock partner Nimish Shah to speak about the significance of innovation and creativity across all aspects of a business. Coric dives into the challenges of launching Biohaven’s drug, Nurtec ODT, during the pandemic and why he believed it was their moral duty to continue the drug supply chain, despite the lockdown. Still seeing patients today, Coric discusses how his patient-centric approach positively guided him as a drug developer. Coric touches on Biohaven’s collaboration with Khloe Kardashian for Nurtec’s launch and his excitement for the digital transformation occurring in biotech. Coric also advises other biotech CEOs raising a cross-over round or going public to be selective with the investors they invite in, as they become an extension of the team.

Vlad Coric, M.D., CEO of Biohaven Pharmaceuticals, joins Venrock partner Nimish Shah to speak about the significance of innovation and creativity across all aspects of a business. Coric dives into the challenges of launching Biohaven’s drug, Nurtec ODT, during the pandemic and why he believed it was their moral duty to continue the drug supply chain, despite the lockdown. Still seeing patients today, Coric discusses how his patient-centric approach positively guided him as a drug developer. Coric touches on Biohaven’s collaboration with Khloe Kardashian for Nurtec’s launch and his excitement for the digital transformation occurring in biotech. Coric also advises other biotech CEOs raising a cross-over round or going public to be selective with the investors they invite in, as they become an extension of the team.

Venrock partner Nick Beim speaks with Jason Wenk, founder and CEO of Altruist, about his mission to increase the accessibility of great financial advice. Wenk walks through his early entrepreneurial endeavors and explains how they’ve contributed to the creation of Altruist. As his leadership style has evolved over the years, Wenk shares the biggest lesson he’s learned while building Altruist and how he’s embraced the fact that it’s okay to not know everything.

Cyrus Harmon, co-founder and CTO of Olema Oncology, joins Venrock partner Alex Rosen to discuss the history of Olema. Olema had a successful IPO last year and Harmon sheds light on what biotech companies should look for when selecting banks for an IPO and how to build momentum for financing rounds.  He also dives into the factors that led to the founding of Olema and how the company evolved to develop their OP-1250 drug, used for the treatment of estrogen receptor-positive breast cancer. Harmon shares the biggest challenges he encountered, things he would have done differently, and the importance of perseverance as a leader. Harmon also touches on the biotech trends he’s most excited about, including mRNA vaccines, gene therapy, and AI in computational drug discovery. 

Venrock partner Camille Samuels speaks with Angie You, CEO of Amunix, and Rich Heyman, Chairman of the Board, about the dynamics between a CEO and a Chairperson that foster a successful company. You and Heyman dive into the importance of mutual trust and respect between a CEO and the Board, and You shares her passion for people that makes her such a great talent hunter. You shares her experience as an Asian female CEO that has busted through multiple ceilings, and how her supportive friends and network help to make the CEO’s role less lonely. They also discuss how they’ve built an incredibly diverse management team at Amunix and why diversity of thought is so important.

Eric Brown, CEO of Dynamic Signal, joins Venrock partner Brian Ascher to speak about diversity, equity, and inclusion. Brown believes you can’t have great culture without putting inclusion first, which is why it was the first thing on his agenda as he stepped into his role as CEO of Dynamic Signal last year. Brown discusses some of the company’s initiatives, including the Mentorship and Access program, and shares how these programs have been received so far. Brown also shares the challenges of balancing family and work and how he had to purposefully make space for each of them to exist in harmony.

Venrock Partner Mike Tyrrell speaks with Jason Purcell, co-founder and CEO of Salsify to discuss his career and how Endeca’s $1B exit lead to the creation of Salsify. Purcell explains how we are in the midst of a “masses of markets” world, and delves into how commerce experience management platforms like Salsify are helping brands navigate a space where consumers engage with products on a broad variety of channels and win on the digital shelf. Purcell shares the toughest part of his journey at Salsify and what the company sees as its “North Star”. They also discuss the importance of repeated clear communication in leadership strategy, particularly when a company grows past the startup stage.  

Dataminr uses AI to detect when major events are happening, long before the first news reports emerge. How is this possible? Venrock’s Nick Beim chats with Dataminr’s co-founder and CEO Ted Bailey to discuss how the rise of real-time data platforms and misinformation around the 9/11 attacks helped spark the idea for the company. He shares how Dataminr helps clients mitigate and respond to potential crises more effectively, including the ongoing pandemic. They also discuss how the Dataminr workforce is responding to all-remote work and how Bailey has grown as a leader since founding the company in 2009. 

Emily Drabant Conley, CEO of Federation Bio, joins Venrock partner Racquel Bracken to chat about lessons learned from her time at 23andMe and how Federation Bio is disrupting the microbiome space. Conley discusses key takeaways from her experience in handling moments of crisis, including the importance of transparency and staying consistent with your company’s mission. As a female CEO, Conley shares what traits of 23andMe’s Anne Wojcicki she tries to emulate and discusses how setting aggressive goals has helped her career. Conley also discusses the opportunities that come with working at a small company and reveals her passion for cooking, which she’s ramped up during the pandemic.

Venrock partner Nimish Shah speaks with Jason Fenton, managing director and head of healthcare capital markets at Cowen, to discuss the explosion of activity in the biotech IPO market this year. Fenton dives into the pros and cons of a virtual IPO process and shares best practices for companies looking to go public. Shah and Fenton outline some of the important factors to consider when choosing bankers and touch on common mistakes CEOs make while going through an IPO. Fenton also walks through the components of a recent successful IPO deal and provides his expectations for the biotech market in 2021. 

Ryan Nece is a former NFL player, Super Bowl winner, and now a venture capitalist at Next Play Capital. He joins Venrock partner Brian Ascher to chat about the transition from the field to the boardroom, including why so many professional athletes take an interest in venture capital and what elite athletes and successful entrepreneurs have in common. Nece shares the highs and lows of having a famous parent, football Hall of Famer Ronnie Lott, and his gratitude for the opportunities made possible by his upbringing. No stranger to adversity, he also discusses a challenging time battling injuries that almost ruined his career before it started. 

Venrock partner Bob Kocher speaks with Hill Ferguson, CEO of Doctor On Demand, about how the company managed a huge spike in demand for virtual care as COVID-19 spread throughout the country beginning in March 2020. He shares how Doctor On Demand implemented a real-time assessment for higher-risk patients to handle growing wait times, and how they partnered with Medicare to cover virtual care visits for seniors for the first time. Kocher and Ferguson discuss how social injustice, economic hardship, and losing loved ones to COVID-19 are contributing to the increased demand in behavioral health services offered by Doctor on Demand. Ferguson also highlights the importance of balance and self-care, shares his expectations for flu season, and unpacks Doctor On Demand’s plan to make primary care more accessible through virtual visits. 

Jennifer Bisceglie, CEO and founder of Interos, joins Venrock partner Nick Beim to discuss how Interos mitigates the challenges of third party risk management, particularly during the pandemic, by providing customers full visibility of their extended supply chain. Bisceglie describes how Interos continuously builds “family trees” of companies and scans for risk factors so customers can gain visibility into their supply chains and understand the vulnerabilities that can interrupt operations. She shares her proudest moments at Interos so far, the biggest challenge that female entrepreneurs face, and provides advice to women who are looking to start a business.

Venrock partner Camille Samuels speaks with Corvidia co-founders Ram Aiyar and Michael Davidson about Corvidia’s recent acquisition by Novo Nordisk, just four years after its founding. They discuss how inflammation contributes to cardiovascular disease – the number one killer in the United States – and how their drug Ziltivekimab “Zilti” is proving to be a successful therapy. Aiyar and Davidson share their experiences and advice for other companies exploring a sale, including always being ready for Plan B (or C), maintaining positive relationships, and not rushing any deals. They also discuss why the cardiovascular space is becoming increasingly appealing to entrepreneurs and investors when it was previously avoided. 

Latane Conant, CMO of 6sense, joins Venrock partner Brian Ascher to chat about marketing strategy for B2B companies and the role of marketing in corporate culture. They discuss the “First Sip Club” which Conant started during the pandemic to stay connected to fellow SaaS marketers, and she shares how it has evolved to stay relevant in a rapidly changing environment. Conant also discusses her new book No Forms, No Spam, No Cold Calls: The Next Generation of Account-Based Sales and Marketing, which covers her distinct B2B marketing and sales philosophy, and gives advice for junior marketers looking to excel in their careers.

Healthcare industry veteran George Barrett joins Venrock partner Bob Kocher to discuss how the U.S. handled the unprecedented demand for PPE (personal protective equipment) for healthcare providers during the COVID-19 pandemic. Barrett explains the significance of examining all components at the supply chain level to create a system that is more flexible and resilient. They also delve into Barrett’s non-traditional business background and how his musical talents have shaped his career. 

Venrock partner David Pakman speaks with Roham Gharegozlou, CEO and founder of Dapper Labs about launching CryptoKitties, one of the world's first and most successful blockchain games, and shares his predictions for how crypto gaming will evolve in the next decade. They also discuss the launch of NBA Top Shot, a new kind of digital collectible that capitalizes on consumer affinity for collecting and sports, and Flow, which is a blockchain that takes care of the underlying technology so developers can focus on building their applications. 

Following up on their discussion of COVID-19 vaccines and therapeutics, Venrock partner Bryan Roberts speaks with Mathai Mammen, Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, about Mammen’s career path and what differences he’s found working on drug development in both small companies and large companies. Managing 14,000 people has its challenges, but the scale is incredible: J&J’s products touch more than 1 billion people worldwide. They also discuss trends in gene editing and CRISPR thanks to machine learning and AI.